Variable | HR (95% CI) | SE | P value |
Age | 1.00 (0.98 to 1.01) | 0.01 | 0.556 |
Female sex | 0.87 (0.58 to 1.29) | 0.17 | 0.475 |
Married/with a life partner | 0.80 (0.53 to 1.20) | 0.17 | 0.276 |
Charlson Comorbidity Index score | 1.04 (0.78 to 1.37) | 0.15 | 0.800 |
Double hit lymphoma diagnosis | 1.39 (0.87 to 2.22) | 0.33 | 0.171 |
Number of prior therapies | 1.05 (0.94 to 1.18) | 0.06 | 0.397 |
Prior autologous stem cell transplant | 0.53 (0.32 to 0.88) | 0.14 | 0.013 |
Months from relapse to CAR T-cell infusion | 0.86 (0.68 to 1.07) | 0.10 | 0.180 |
Vein-to-vein time (months) | 0.85 (0.54 to 1.33) | 0.19 | 0.471 |
ECOG performance status | 1.23 (0.98 to 1.54) | 0.14 | 0.078 |
LDH >500 (U/L, prior to CAR T-cell infusion) | 2.04 (1.28 to 3.24) | 0.48 | 0.003 |
CRP >30 (mg/L, prior to CAR T-cell infusion) | 2.10 (1.43 to 3.08) | 0.41 | <0.001 |
Ferritin ≥411 (µg/L, prior to CAR T-cell infusion) | 1.10 (0.73 to 1.68) | 0.24 | 0.645 |
Platelet count <100 K/µL | 1.31 (0.84 to 2.03) | 0.29 | 0.228 |
Bridging therapy use | 1.50 (1.02 to 2.20) | 0.29 | 0.041 |
CD28 co-stimulatory domain CAR T-cell product | 0.64 (0.39 to 1.04) | 0.16 | 0.072 |
Dexamethasone dose (dg) from days 0–31 | 1.08 (1.00 to 1.18) | 0.05 | 0.081 |
Receipt of tocilizumab | 0.63 (0.43 to 0.92) | 0.12 | 0.018 |
CAR, chimeric antigen receptor; CRP, C-reactive protein; dg, decigram; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.